

## List of Publications (Publikationsliste, Stand 02.01.2018)

### A. Vollpublikationen

2001

1. V. Möbus, **C. Uleer**, R. Kreienberg (2001): Systemische Therapie des Zervixkarzinoms. Der Onkologe 7:880-888

2002

2. **C. Uleer**, I. Machill, V. Möbus (2002): Individueller Heilversuch und Therapiefreiheit. Gynäkologische Praxis 26:213-218

2006

3. C. Wüster, I. Lutz, J. Y. Pourfard, **C. Uleer**, G. Felmet (2006): Proprioceptives Vibrationstraining – Physiologische Grundlagen und medizinische Anwendungsbereiche Prevention Anti Aging 2: 496-503

2009

4. **C. Uleer**, K. Samse, N. Uleer (2009): Mammographiescreening Hildesheim – Göttingen – Hameln Breast Care 2009; 4:51-54, DOI: 10.1159/000197353, 10. Februar 2009
5. G. v. Minckwitz, A. du Bois, M. Schmidt, N. Maass, T. Cufer, F. E. de Jongh, E. Maartense, C. Zielinski, M. Kaufmann, W. Bauer, K. H. Baumann, M. R. Clemens, R. Duerr, **C. Uleer**, M. I Andersson, R. C. Stein, V. Nekljudova, and S. Loibl (2009): Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor2-Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study. J Clin Oncol 2009 Apr 20;27(12):1999-2006

2010

6. **C. Uleer** (2010): Wissenswertes vom SABCS 2009. Bericht vom 32. San Antonio Breast Cancer Symposium; Der Frauenarzt 02 (52): 140-148

2011

7. Georg Richter, **Christoph Uleer**, Thomas Noesselt (2011): Multifocal invasive ductal breast cancer with osteoclast-like giant cells: a case report. Journal of Medical Case Reports 2011, 5:85 doi:10.1186/1752-1947-5-85

2012

8. **Uleer C**, Yazdan-Pourfard J, Holland B, Bürrig KF, Moisisdis-Tesch C, von Minckwitz G (2012): Long-Term Partial Remission with Capecitabine/Trastuzumab in a Patient with Metastatic Breast Cancer Following Progression on Trastuzumab Alone. Breast Care 2012;7:45-47
9. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminin A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; **ICON7 Investigators**. (2012): A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2484-96. Erratum in: N Engl J Med. 2012 Jan 19;366(3):284

2013

10. Goss PE, Smith IE, O'Shaughnessy J, Ejlertsen B, Kaufmann M, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Chavarri-Guerra Y, Aktan G, Rappold E, Williams LS, Finkelstein DM; **TEACH investigators** (2013): Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 2013 14(1):88-96. doi:10.1016/S1470-20
11. **Uleer C**, Wagner J, Moisisdis-Tesch C (2013): Relevance of Health Economics in Early Detection of Breast Cancer in Germany – the View of the Professional Association of Practicing Gynecologic Oncologists e.V. (BNGO) Breast Care 2013;8:35-39

2014

12. Nitz U, Gluz O, Zuna I, Oberhoff C, Reimer T, Schumacher C, Hackmann J, Warm M, **Uleer C**, Runde V, Dünnebacke J, Belzl N, Augustin D, Kates RE, Harbeck N; West German Study Group (2014): Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbeopetin alfa on event-free survival in early breast cancer. *Ann Oncol.* 2014 Jan;25(1):75-80. doi: 10.1093/annonc/mdt505.
13. Cuzick J1, Sestak I2, Forbes JF3, Dowsett M4, Knox J2, Cawthorn S5, Saunders C6, Roche N7, Mansel RE8, von Minckwitz G9, Bonanni B10, Palva T11, Howell A12; **IBIS-II investigators** (2014) Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. *Lancet.* 2014 Mar 22;383(9922):1041-8. doi: 10.1016/S0140-6736(13)62292-8. Epub 2013 Dec 12.
14. Von Schumann R, Gluz O, Hofmann D, Kates RE, Clemens M, Reimer T, Liedtke B, Aktas B, Stefek A, Pollmanns A, Lorenz-Salehi, Uleer C, Krabisch P, Augustin D, Harbeck N, Nitz U (2014): Febrile neutropenia (FN) and infections under adjuvant chemotherapy of breast cancer with 6 x TC vs. 4 x EC-4 x Doc: Toxicity data of the WSG planB trial. *Oncology Research and Treatment* 37:14-15 · February 2014.
15. Csef H, Hefner J, Hönig A, Otto C., Schilling J., Sokol C., **Uleer C.** (2014): Optimiertes Management des fortgeschrittenen Mammakarzinoms, Modul Psychoonkologie Pharmawissen aktuell 402708 in best practice onkologie 3-4/2014 *Der Gynäkologe* 7/2014
16. J Schilling, C Uleer, S Busch (2014): Neoadjuvante Chemotherapie bei Mammakarzinom-Patientinnen – die Behandlungsrealität in gynäko-onkologischen Praxen des BNGO. *Senologie - Zeitschrift für Mammadiagnostik und -therapie* 2014; 11 - A106, DOI: 10.1055/s-0034-1375465
17. v Minckwitz, Loibl S, Untch M., Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Houber J, Solbach C, Jackisch C, Kunz G Blohmer JU, Hauschild JM, Fehm T, Nekljudova V, Gerber B for the GBG/AGO-B study groups (2014): Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44 – **GeparQuinto**) *Ann Oncol* (2014) Sept 15 doi: 10.1093/annonc/mdu455
18. EM Grischke, D Lüftner, F Schütz, P Wimberger, F Förster, T Decker, **C Uleer**, M Muth, J Kreuzeder, W Bloch, H Tesch, C Jackisch, PA Fasching (2014): Breast Cancer Treatment with Afinitor® (Everolimus) and Exemestane for ER+ Women – Ergebnisse der ersten Interimsanalyse der nicht-interventionellen Studie BRAWO. *Senologie - Zeitschrift für Mammadiagnostik und -therapie* 2014; 11 - A43, DOI: 10.1055/s-0034-1375402

2015

19. D. Lüftner · E.M. Grischke · P. Fasching · T. Decker · A. Schneeweiss · **C. Uleer** · F. Foerster · P. Wimberger · B. Kluth-Pepper · J. Schubert · W. Bloch · H. Tesch · F. Schuetz · C. Jackisch (2015): 1869 Disease characteristics of subgroup patients treated with everolimus + exemestane for <12 months, ≥12 to <18months, and ≥18 months - Results of the 3rd interim analysis of the non-interventional trial BRAWO *EJC Volume 51, Supplement 3, Pages S288–S289*
20. E Trapp, B Rack, C Messina, V Müller, T Fehm, W Janni, A Schramm, C Löhberg, P Wimberger, **C Uleer**, O Brudler, C Sotiriou, J Pierga, M Piccart, M Ignatiadis (2015): TREAT CTC – Ein innovativer Ansatz zur Therapie von zirkulierenden Tumorzellen (CTCs) beim frühen Mammakarzinom. *Senologie - Zeitschrift für Mammadiagnostik und -therapie* (2015); 12 - A139, DOI: 10.1055/s-0035-1550581
21. Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; **ICON7 trial investigators. Collaborators aot Uleer, C.** (2015): Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. *Lancet Oncol.* 2015 Aug; 16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8

2016

22. C. M. Moisisidis-Tesch · N. A. Ginsberg · **C. Uleer** · Volker J. Möbus (2016): The Role of Cervical Cultures to Guide Perioperative Antibiotics in Cervical Cerclage- a Retrospective Analysis of 65 Consecutive Cases Journal of Maternal-Fetal and Neonatal Medicine · January 2016
23. du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium. Collaborators aot Uleer, C. (2016): Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2016 Jan; 17(1):78-89. doi: 10.1016/S1470-2045(15)00366-6

2017

24. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators incl. **C. Uleer**; Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer; N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5

## **B. Kongressbeiträge/Abstracts**

1996

1. **C. Uleer**, H. G. Meerpohl (1996):Terapia del dolore in pazienti affette da un tumore ginecologico; principi di trattamento e aspetti etici. Vortrag auf dem Jahreskongress der italienischen Gerichtsmediziner in Modena, Italien: „Sessualita' e Diritto“

2000

2. F. Hilpert, T. Zeiser, S. Markmann, J. Quaas, T. Menschlik, A. Nugent, S. Buchholz, S. Flachsenberg, H. J. Bettex, **C. Uleer**, J. Pfisterer für die AGO-Studiengruppe Ovarialkarzinom, Sektion Nord (2000): Epirubicin/Carboplatin/Taxol vs. Carboplatin/Taxol als 1<sup>st</sup>-line Chemotherapie beim fortgeschrittenen Ovarialkarzinom. Interimsanalyse einer randomisierten Phase III-Studie der AGO-Studiengruppe Ovarialkarzinom

2008

3. **C. Uleer**, J. Y. Pourfard (2008): Klinische Sonderfälle in der interdisziplinären Brustkonferenz Senologie, Abstracts der 28. Jahrestagung der Deutschen Gesellschaft für Senologie #147

2009

4. U. Nitz, C. Oberhoff, T. Reimer, C. Schumacher, J. Hackmann, M. Warm, **C. Uleer**, V. Runde, O. Gluz, I. Zuna (2009): Adjuvant chemotherapy with or without darbeopetin in node-positive breast cancer: a safety analysis from the phase III ARA plus trial. Cancer Res 2009; 69(2 Suppl): SABCS 2008 Abstract nr 4100

2010

5. E.-J. Kantelhardt, V. Hanf, F. Weiß, C. Ehrke, T. Lantzsch, **C. Uleer**, K.-F. Bürrig, C. Thomssen (2010) PIA-Studie - Prognosefaktoren im Alltag bei Patientinnen mit neu diagnostiziertem operable Mammakarzinom: Risikoabschätzung anhand der Prognosemarker uPA/PAI-1. Senologie, Abstracts der 30. Jahrestagung der Deutschen Gesellschaft für Senologie # 75
6. Degenhardt T., Gluz O., Thomssen C., Vetter M., Kates R., Warm M., Shak S., Augustin D., Kusche M., Untch M., Paepcke S., **Uleer C.**, Dünnebacke J. Nitz U., Harbeck N. (2010): Risk Group Selection in Primary Breast Cancer According to ASCO Recommended Biomarkers Oncotype DX and uPA and PAI-1: First Experience from Prospective Multicenter WSG Plan B Trial. Cancer Res 2011; 70(2 Suppl): SABCS 2010 Abstract nr P2-09-05

2011

7. **C. Uleer**, J.Yazdan Pourfard , V. Möbus (2011): Das dosisdichte und dosisintensivierte ETC-Chemotherapieprotokoll in der gynäkologisch-onkologischen Praxis Abstracts der 31. Jahrestagung der Deutschen Gesellschaft für Senologie #078
8. Witzel ID, Loibl S, von Minckwitz G, Abdallah A, Kühn T, Overkamp F, Fehm T, Schrader I, **Uleer C**, Kohls A, Stirnberg S, zu Eulenburg C, Untch M, Müller V (2011) Predictive Value of HER2 Predictive Value of HER2 Serum Levels in Patients Treated with Lapatinib or Trastuzumab – A Translational Project in the Neoadjuvant “Geparquinto” Trial Cancer Research 2011, 71 (27) Suppl. SABCS 6.-10.12.2011 # P4-08-01
9. Nitz U, Gluz O, Oberhoff C, Reimer T, Schumacher C, Hackmann J, Warm M, **Uleer C**, Runde V, Kümmel S, Zuna I, Harbeck N (2011) Adjuvant Chemotherapy with or without Darbepoetin alpha in Node Positive Breast Cancer: Survival and Quality of Life Analysis from the Prospective Randomized WSG ARA Plus Trial Cancer Research 2011, 71 (27) Suppl. SABCS 6.-10.12.2011 #PD 0706
10. Gluz O, Kreipe H, Degenhardt T, Kates R, Christgen M, Liedtke C, Shak S, Clemens M, Markmann S, **Uleer C**, Augustin D, Thomssen C, Nitz U, Harbeck N (2011) Prospective Comparison of Risk Assessment Tools in Early Breast Cancer (Recurrence Score, uPA/PAI-1, Central Grade, and Luminal Subtypes): Final Correlation Analysis from the Phase III WSG-Plan B Trial Cancer Research 2011, 71 (27) Suppl. SABCS 6.-10.12.2011 #S4-3

2012

11. Oleg Gluz, Hans Heinrich Kreipe, Matthias Christgen, Tom Degenhardt, Ronald E. Kates, Cornelia Liedtke, Steven Shak, Michael R. Clemens, Marwa Salem, Susanne Markmann, Bernd Liedtke, Bahriye Aktas, Stephan Henschen, Anke Pollmanns, Petra Krabisch, **Christoph Uleer**, Doris Augustin, Christoph Thomssen, Ulrike Nitz, Nadia Harbeck (2012) Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial. J Clin Oncol 30, 2012 (suppl; abstr 552) 2012
12. Gluz O, Kreipe HH, Kates RE, Christgen M, Liedtke C, Shak S, Clemens M, Salem M, Liedtke B, Aktas B, Markmann S, **Uleer C**, Augustin D, Thomssen C, Nitz U, Harbeck N (2012) Prospective Comparison of Recurrence Score and Different Definitions of Luminal Subtypes by Central Pathology Assessment of Single Markers in Early Breast Cancer: Results from the Phase III WSG-planB Trial Cancer Research 2012, 72:P2-10-08; doi:10.1158/0008-5472.SABCS12-P2-10-08

2013

13. V.r Moebus, H. Forstbauer, G. Wachsmann, A. Schneeweiss, A. Ober, E. von Abel, P. Krabisch, H.-G. Hoeffkes, K. Kast, B. Christensen, M. Niedermeier, M. Deryal, **C. Uleer**, Y. Fauster, T. Goehler, S. Loibl, V. Nekljudova, G. von Minckwitz, (2013): Adjuvant phase III trial to compare intense dose-dense adjuvant treatment with EnPC to dose dense, tailored therapy with dtEC-dtD for patients with high-risk early breast cancer (GAIN-2). ASCO MEETING ABSTRACTS Jun 17, 2013:TPS1137
14. Von Schumann R, Gluz O, Hofmann D, Kates RE, Clemens M, Reimer T, Liedtke B, Aktas B, Stefek A, Pollmanns A, Lorenz-Salehi, **Uleer C**, Krabisch P, Augustin D, Harbeck N, Nitz U (2013): Febrile Neutropenien (FN) und Infektionen unter adjuvanter Chemotherapie des Mammakarzinoms mit 6xTC vs. 4xEC-4xDoc: Toxizitätsdaten der WSG planB Studie 33. Jahrestagung der dt. Gesellschaft für Senologie # 90
15. Wuerstlein R, Gluz O, Kreipe HH, Kates RE, Christgen M, Liedtke C, Shak S, Clemens M, Salem M, Liedtke B, Aktas B, Markmann S, **Uleer C**, Augustin D, Hofmann D, Thomssen C, Nitz U, Harbeck N. WSG plan-B trial: Comparison of recurrence score and definitions of luminal subtypes 2013 St. Gallen International Breast Cancer Conference # 151

2014

16. F. Hilpert, P. Wimberger, J. Sehoul, A. Reuß, P. Harter, R. Hils, N. de Gregorio, H.-J. Lück, B. Gerber, T. Fehm, L. Hanker, **C. Uleer**, A. Burges, J. Kosse, M. Thill, M. Beckmann, J.-P. Scharf, W. Meier, G. Gebauer, E. Pujade-Lauraine (2014): Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC). Deutscher Krebskongress 2014
17. Lüftner D, Schütz F, Grischke E, Fasching P, Wimberger P, Förster F, Decker T, **Uleer C**, Muth M, Kreuzeder J, Bloch W, Tesch H, Jackisch C (2014): Breast Cancer Treatment with Everolimus and Exemestane for ER+ Women - Results of the first interim analysis of the non-interventional trial BRAWO. ASCO-Meeting Abstract # ID 578
18. C. Jackisch, E.-M. Grischke, A. Schneeweiss, T. Decker, **C. Uleer**, F. Förster, O. Tomé, P. Wimberger, C. M Kurbacher, B. Mueller, N. Harbeck, C.h Mundhenke, S. Kuemmel, M. Muth, J. Kreuzeder, W. Bloch, H. Tesch, D. Lüftner, F. Schütz, P. A Fasching (2014): Abstract P5-19-12: Subgroup analysis on efficacy in the routine treatment - Results of the 2nd interim analysis of BRAWO, the non-interventional trial "Breast Cancer Treatment with Everolimus and Exemestane for HR+ Women". 37. CTRC-AACR San Antonio Breast Cancer Symposium
19. Martina Vetter, Kristin Reinhardt, Silke Wegener, Juergen Dittmer, Tilmann Lantzs, **Christoph Uleer**, Susanne Peschel, Jutta John, Volker Hanf, Joerg Buchmann, Karl-Friedrich Bürrig, Edith Weigert, Christoph Thomssen, Eva J Kantelhardt (2014): Abstract P1-04-06: Prevalence of PIK3CA mutations in tumor tissue of a consecutive cohort of breast cancer patients (n=700). 37. CTRC-AACR San Antonio Breast Cancer Symposium
20. Fasching P A, Decker T, Schneeweiss A, **Uleer C**, Förster F, Wimberger P, Kurbacher CM, Harbeck N, Tome' O., Müller B, Mundhenke C, Kümmel S, Muth M, Kreuzeder J, Bloch W, Tesch H, Lüftner D, Jackisch C, Schütz F, Grischke E (2014): Breast cancer treatment with everolimus and exemestane for ER+ women - Results of the 2nd interim analysis of the non-interventional trial BRAWO. ESMO Conference Abstract # LBA9

2015

21. Oleg Gluz · Ulrike Nitz · Matthias Christgen · Eva-Maria Grischke · Helmut Forstbauer · Michael Wilhelm Braun · Mathias Warm · **Christoph Uleer** · Bahriye Aktas · Claudia Schumacher · [...] · Thill M · Kohls A · Kümmel S · Perlova-Griff L · Cornelia Liedtke · Hofmann D · Kates RE · Rachel Wuerstlein · Hans Heinrich Kreipe · Nadia Harbeck · (2015) Efficacy of 12 weeks neoadjuvant Nab-Paclitaxel combined with Carboplatinum vs. Gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial. 2015 ASCO Annual Meeting |Abstract No: 506|
22. **C Uleer**, J Yazdan Pourfard, C Moisisdis-Tesch, G von Minckwitz (2015): Fallbericht: Langzeitüberleben eines Her2 positiven, metastasierten Mammakarzinoms durch eine Trastuzumab-haltige Kombinationsbehandlung nach dem Therapieprinzip „TBP“. Senologie - Zeitschrift für Mammadiagnostik und -therapie 2015; 12 - A141, DOI: 10.1055/s-0035-1550583
23. Bloch W · Baumann F · Zimmer P · Grischke E M · Fasching PA · Decker T · **Uleer C** · Schneeweiss A · Salat C · Wimberger P · Mundhenke C · Förster F · Kluth-Pepper B · Schubert J · Tesch H · Schütz F · Lüftner D · Jackisch C (2016): Impact of physical activity/exercise on adverse events and quality of life during treatment with everolimus and exemestane for ER+ women - Results of the 3rd interim analysis of BRAWO Cancer Research 76(4 Suppl): P4-13-07

2017

24. S. Bernhardt, M. Bayerlová, M. Vetter, A. Wachter, D. Mitra, V. Hanf, T. Lantzs, **C. Uleer**, S. Peschel, J. John, J. Buchmann, E. Weigert, K.-F. Bürrig, C. T., U. Korf, T. Beissbarth, S. Wiemann and E. J. Kantelhardt; Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors; Breast Cancer Research 2017; 19:112; doi:10.1186/s13058-017-0905-7